Bone sarcoma is an umbrella term for a group of malignant primary tumors that arise from cells within the bone. Several recognized subtypes have been described, including osteosarcoma, Ewing sarcoma of bone, chondrosarcoma (with several variants), undifferentiated pleomorphic sarcoma of bone, fibrosarcoma of bone, leiomyosarcoma of bone, and giant cell tumor of bone. Each subtype has its own cell of origin, age distribution, and clinical behavior. Osteosarcoma and Ewing sarcoma most often affect children, adolescents, and young adults, while chondrosarcoma typically presents in middle-aged and older adults. As a group, bone sarcomas are uncommon. Most cases occur sporadically, although a small subset are linked to hereditary cancer predisposition syndromes or prior radiation therapy. Care is highly specialized and is best delivered at centers experienced in orthopedic and medical oncology. This summary reflects clinical data available as of the latest knowledge packet.

Symptoms of bone sarcoma vary by subtype and tumor location. Persistent localized bone pain is the most frequent presenting symptom and may worsen at night or with activity. A palpable mass or visible swelling near a bone, often around the knee, hip, shoulder, or pelvis, may develop as the tumor grows. Reduced range of motion, limping, or difficulty bearing weight can occur when a tumor involves a long bone. Some individuals first come to attention because of a pathologic fracture, in which a bone breaks with little or no trauma. Systemic features such as fatigue, unintended weight loss, or fever can occur, particularly in Ewing sarcoma and in advanced disease. Not all individuals experience all features, and severity varies considerably.

Most bone sarcomas occur sporadically and are thought to arise from somatic genetic changes that develop in bone-forming or connective tissue cells over a person's lifetime, rather than from inherited genetic variants. A small proportion of cases occur in the context of inherited cancer predisposition syndromes such as Li-Fraumeni syndrome, hereditary retinoblastoma, and Rothmund-Thomson syndrome, or in the setting of Paget disease of bone, which can increase the risk of certain bone sarcomas, particularly osteosarcoma. Prior therapeutic radiation can also raise the risk of a subsequent bone sarcoma in the irradiated field years later. Because bone sarcoma is a family of distinct diseases rather than a single condition, there is no single inheritance pattern. Genetic counseling and testing may be considered when features suggest a hereditary cancer syndrome.

Diagnosis of bone sarcoma typically begins when persistent bone pain, swelling, or an unexplained pathologic fracture prompts imaging studies. Plain radiographs are often the first test and can show characteristic patterns of bone destruction or new bone formation. Magnetic resonance imaging defines the local extent of the tumor, while computed tomography of the chest and whole-body imaging such as bone scan or PET-CT evaluate for metastatic disease. The diagnosis is confirmed by biopsy, which should be planned in coordination with the surgical team that will perform definitive resection. Symptoms can overlap with benign bone lesions, metastatic carcinoma, lymphoma, or infection, so expert pathologic review is essential. Molecular and cytogenetic testing of the biopsy sample helps confirm the specific subtype, particularly for Ewing sarcoma.

Treatment of bone sarcoma depends on the specific subtype, tumor location, size, grade, and the presence or absence of metastatic disease, and is best delivered by an experienced multidisciplinary sarcoma team. Surgical resection of the primary tumor with adequate margins is a cornerstone of management for most subtypes, and advances in limb-sparing surgery now allow many patients to avoid amputation. Osteosarcoma and Ewing sarcoma are typically treated with combination chemotherapy given before and after surgery to address microscopic disease. Conventional chondrosarcoma is generally less responsive to chemotherapy and radiation, and surgery is usually the primary treatment. Radiation therapy is an important component of care for Ewing sarcoma. There are no FDA-approved disease-specific therapies that apply uniformly across all bone sarcomas; regimens are subtype-specific and are guided by oncology specialists. Supportive care includes pain management, rehabilitation, psychosocial support, and fertility preservation counseling. Regular surveillance is an essential part of long-term care to monitor for recurrence, metastasis, and late effects of therapy.

Outcomes in bone sarcoma vary widely and depend strongly on the subtype, tumor stage at diagnosis, location, response to initial treatment, and individual patient factors. Localized disease that can be completely resected generally has a more favorable outlook than disease that has spread at diagnosis. Advances in combined chemotherapy and surgery have substantially improved survival for younger patients with osteosarcoma and Ewing sarcoma, and limb-sparing surgery has improved long-term function for many. Chondrosarcoma outcomes are largely tied to grade and to the completeness of surgical resection. Metastatic disease, most often involving the lungs, is associated with lower survival, although meaningful responses are still possible. Long-term follow-up is important to monitor for recurrence and for late effects of treatment.

Bone sarcoma is an active area of research, with numerous ongoing clinical trials investigating new treatments and refined approaches to existing therapies. Current studies include early-phase trials of engineered cell therapies, such as chimeric antigen receptor T cells targeting tumor-associated antigens, and T-cell-based therapies designed to deliver immune signals directly to bone and soft tissue sarcomas. Other trials are evaluating combinations of radiation, chemotherapy, and targeted agents in the preoperative setting, as well as oncolytic and other investigational platforms. Research is also examining tumor biomarkers that may help predict response to therapy and refine risk stratification. Individuals interested in clinical trials can search ClinicalTrials.gov or consult their care team.